|
1.
|
Shin HR, Joubert C, Boniol M, et al:
Recent trends and patterns in breast cancer incidence among Eastern
and Southeastern Asian women. Cancer Causes Control. 21:1777–1785.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
American Cancer Society: Cancer Facts
& Figures 2007. ACS Publication; Atlanta GA: 2007
|
|
3.
|
Tan EM and Zhang J: Autoantibodies to
tumor-associated antigens: reporters from the immune system.
Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Zhang JY and Tan EM: Autoantibodies to
tumor-associated antigens as diagnostic biomarkers in
hepatocellular carcinoma and other solid tumors. Expert Rev Mol
Diagn. 10:321–328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Soussi T: p53 Antibodies in the sera of
patients with various types of cancer: a review. Cancer Res.
60:1777–1788. 2000.PubMed/NCBI
|
|
6.
|
Looi K, Megliorino R, Shi FD, Peng XX,
Chen Y and Zhang JY: Humoral immune response to p16, a
cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep.
16:1105–1110. 2006.PubMed/NCBI
|
|
7.
|
Yamamoto A, Shimizu E, Takeuchi E, et al:
Infrequent presence of anti-c-Myc antibodies and absence of c-Myc
oncoprotein in sera from lung cancer patients. Oncology.
56:129–133. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Disis ML, Pupa SM, Gralow JR, Dittadi R,
Menard S and Cheever MA: High-titer HER-2/neu protein-specific
antibody can be detected in patients with early-stage breast
cancer. J Clin Oncol. 15:3363–3367. 1997.PubMed/NCBI
|
|
9.
|
Zhang JY, Chan EK, Peng XX and Tan EM: A
novel cytoplasmic protein with RNA-binding motifs is an autoantigen
in human hepatocellular carcinoma. J Exp Med. 189:1101–1110. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Doyle GA, Bourdeau-Heller JM, Coulthard S,
Meisner LF and Ross J: Amplification in human breast cancer of a
gene encoding a c-myc mRNA-binding protein. Cancer Res.
60:2756–2759. 2000.PubMed/NCBI
|
|
11.
|
Soo Hoo L, Zhang JY and Chan EK: Cloning
and characterization of a novel 90 kDa ‘companion’ auto-antigen of
p62 overexpressed in cancer. Oncogene. 21:5006–5015. 2002.
|
|
12.
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Megliorino R, Shi FD, Peng XX, et al:
Autoimmune response to anti-apoptotic protein survivin and its
association with antibodies to p53 and c-myc in cancer detection.
Cancer Detect Prev. 29:241–248. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Daniels T, Zhang J, Gutierrez I, et al:
Antinuclear autoantibodies in prostate cancer: immunity to
LEDGF/p75, a survival protein highly expressed in prostate tumors
and cleaved during apoptosis. Prostate. 62:14–26. 2005. View Article : Google Scholar
|
|
15.
|
Crawford LV, Pim DC and Bulbrook RD:
Detection of antibodies against the cellular protein p53 in sera
from patients with breast cancer. Int J Cancer. 30:403–408. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Winter SF, Minna JD, Johnson BE, Takahashi
T, Gazdar AF and Carbone DP: Development of antibodies against p53
in lung cancer patients appears to be dependent on the type of p53
mutation. Cancer Res. 52:4168–4174. 1992.PubMed/NCBI
|
|
17.
|
Anderson KS and LaBaer J: The sentinel
within: exploiting the immune system for cancer biomarkers. J
Proteome Res. 4:1123–1133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Zhang JY, Casiano CA, Peng XX, Koziol JA,
Chan EK and Tan EM: Enhancement of antibody detection in cancer
using panel of recombinant tumor-associated antigens. Cancer
Epidemiol Biomarkers Prev. 12:136–143. 2003.PubMed/NCBI
|
|
19.
|
Chen WQ: Assessing the validity and
reliability of screening test. Epidemiology. Li LM: Publishing
Company of the People’s Health; Beijing: pp. 289–292. 2004
|
|
20.
|
Koziol JA, Zhang JY, Casiano CA, et al:
Recursive partitioning as an approach to selection of immune
markers for tumor diagnosis. Clin Cancer Res. 9:5120–5126.
2003.PubMed/NCBI
|
|
21.
|
Zhang JY, Megliorino R, Peng XX, Tan EM,
Chen Y and Chan EK: Antibody detection using tumor-associated
antigen mini-array in immunodiagnosing human hepatocellular
carcinoma. J Hepatol. 46:107–114. 2007. View Article : Google Scholar
|
|
22.
|
Chen Y, Zhou Y, Qiu S, et al:
Autoantibodies to tumor-associated antigens combined with abnormal
alpha-fetoprotein enhance immunodiagnosis of hepatocellular
carcinoma. Cancer Lett. 289:32–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Liu W, Wang P, Li Z, et al: Evaluation of
tumour-associated antigen (TAA) miniarray in immunodiagnosis of
colon cancer. Scand J Immunol. 69:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Chen Y, Lin P, Qiu S, et al:
Autoantibodies to Ca2+ binding protein Calnuc is a
potential marker in colon cancer detection. Int J Oncol.
30:1137–1144. 2007.
|
|
25.
|
Li L, Wang K, Dai L, Wang P, Peng XX and
Zhang JY: Detection of autoantibodies to multiple tumor-associated
antigens in the immunodiagnosis of ovarian cancer. Mol Med Rep.
1:589–594. 2008.PubMed/NCBI
|
